STAT

STAT Plus: Phlow CEO speaks out on criticism of his record, plans for a drug ingredient stockpile, and a huge government contract

STAT spoke with Phlow CEO Eric Edwards about the criticism over his track record, Phlow's plan to create a national drug ingredient stockpile, and the huge government contract the company…
Eric Edwards, the chief executive officer of Phlow.

Earlier this week, the U.S. government a $354 million contract to a new public benefit company called Phlow to make generics that are in short

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks